Healionics key facts
as of Oct 2026- Developer of vascular graft technology designed to improve blood access for dialysis in patients with kidney failure.
- Healionics is valued at approximately $44.5M as of Oct 2026, set at its later-stage round, Dec 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $28.2M across 4 recorded rounds; the latest was Seed Round ($2.0M) in Dec 2025.
- Notable investors include MedTech Innovator, National Institutes of Health, New York Angels, Band of Angels, iSelect Fund — 41 tracked in total.
- Healionics has filed 9 Form Ds with the SEC since 2011, most recently Feb 2024 ($5.5M sold to 70 investors).
- Status: Privately Held (backing).
Valued at $44.5M at its later-stage round, Dec 2025. Nothing has traded since.
- ·The complete investor list: 41 names
- ·Watch Healionics: the Monday email on marks, rounds and moves
Healionics funding rounds
4 roundsWho backs Healionics
41+Healionics valuation
Healionics was valued at $44.5 million at its later-stage round in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Healionics raised?
Healionics has raised $28.2 million across 4 recorded rounds since 2018. The largest was a $6.6 million early-stage round in Dec 2020; the most recent was a $2 million seed round in Dec 2025.
Healionics has filed 9 Form Ds with the SEC since 2011, most recently in Feb 2024 ($5.5 million sold to 70 investors).
Healionics investors
41 investors are on record for Healionics, including MedTech Innovator, National Institutes of Health, New York Angels and Band of Angels. By type, the record holds 3 venture capital firms and 2 angel investors. The seed round in Dec 2025 drew 30 investors.
About Healionics
Developer of vascular graft technology designed to improve blood access for dialysis in patients with kidney failure. The company offers a synthetic blood vessel that reduces the risk of occlusion and infection commonly associated with existing grafts by leveraging a biomaterial scaffold that enables the formation of new blood vessels and healing while reducing foreign body response, minimizing tissue scarring, and imparting high resistance to infection, allowing healthcare providers to deliver safer, more reliable, and cost-effective dialysis treatment.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2007
- Employees
- 10
- Website
- healionics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.